Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome

被引:6
|
作者
Zhao, Ji-Meng [1 ]
Chen, Liu [1 ]
Zhou, Ci-Li [2 ]
Shi, Yin [1 ,2 ]
Li, Yu-Wei [1 ]
Shang, Hai-Xia [1 ]
Wu, Lu-Yi [1 ]
Bao, Chun-Hui [2 ]
Dou, Chuan-Zi [2 ]
Wu, Huan-Gan [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China
[2] Shanghai Inst Acupuncture Moxibust & Meridian, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
5-HT4; RECEPTOR; MAST-CELLS; SEROTONIN; DIARRHEA;
D O I
10.1155/2016/9410505
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Aim. To compare whether there is different effect between electroacupuncture (EA) and moxibustion (Mox) on visceral hypersensitivity (their analgesic effects) in constipation-predominant irritable bowel syndrome (C-IBS). Methods. EA at 1 mA and 3 mA and Mox at 43 degrees C and 46 degrees C were applied to the Shangjuxu (ST37, bilateral) acupoint in rats with C-IBS and normal rats. An abdominal withdrawal reflex (AWR) score was used to assess visceral hypersensitivity. Toluidine blue staining was used to assess mast cell (MC) activity in colon of rats. Immunochemistry was used to measure 5-HT and 5-HT4 receptor expression in the colon. Results. AWR scores in all EA (1 mA and 3 mA) and Mox (43 degrees C and 46 degrees C) treatment groups after colorectal distention (CRD) stimulation pressure of 20, 40, 60, and 80 mm Hg were significantly lower than those of the model (MC) group (P all < 0.01). The MC counts and degranulation rates in the colon of all EA and Mox treatment groups and the MC group were significantly higher than those of the NC group (P all < 0.01). MC degranulation rates in the colon of all EA and Mox treatment groups were lower than those of the MC group (P all < 0.05). 5-HT expression in colon of all EA and Mox treatment groups was significantly lower than that of the MC group (P all < 0.01), and 5-HT4R expression in colon of both EA groups was significantly higher than that of the MC group (P both < 0.01). Conclusion. EA andMox treatments may both ameliorate visceral hypersensitivity at different degree in rats with C-IBS, and EA treatment was better than Mox.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
    Eswaran, Shanti
    Guentner, Amanda
    Chey, William D.
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 20 (02) : 141 - 151
  • [22] Comparison of colonic transit time between patients with constipation-predominant irritable bowel syndrome and functional constipation
    Ansari R.
    Sohrabi S.
    Ghanaie O.
    Amjadi H.
    Merat S.
    Vahedi H.
    Khatibian M.
    Indian Journal of Gastroenterology, 2010, 29 (2) : 66 - 68
  • [23] Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups
    Zar, Sameer
    Benson, Martin J.
    Kumar, Devinder
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (02) : 151 - 158
  • [24] Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide
    Yu, Siegfried W. B.
    Rao, Satish S. C.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2014, 7 (05): : 193 - 205
  • [25] Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo
    Ziegenhagen, DJ
    Kruis, W
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (07) : 744 - 749
  • [26] Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome
    Cui, Li
    Zou, Shuting
    Liu, Jing
    Lv, Huixia
    Li, Hui
    Zhang, Zhenhai
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [27] Constipation-Predominant Irritable Bowel Syndrome Complicating Asymptomatic Nonrotation of the Midgut
    Plackett, Timothy P.
    Myers, Jonathan
    Gagliano, Ronald A., Jr.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (08): : 437 - 440
  • [28] Colchicine Plus Olsalazine for Treatment of Constipation-Predominant Irritable Bowel Syndrome
    Barody, Thomas J.
    Hills, Lauren A.
    Torres, Margaux
    GASTROENTEROLOGY, 2009, 136 (05) : A484 - A484
  • [29] Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome
    Biniszewska, Olga
    Jacenik, Damian
    Tarasiuk, Aleksandra
    Fichna, Jakub
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (08) : 1039 - 1049
  • [30] Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review
    Mosinska, Paula
    Salaga, Maciej
    Fichna, Jakub
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (03) : 275 - 286